Acumen Pharmaceuticals, Inc. (ABOS)
| Market Cap | 162.51M +111.3% |
| Revenue (ttm) | n/a |
| Net Income | -113.28M |
| EPS | -1.85 |
| Shares Out | 72.23M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 176,813 |
| Open | 2.320 |
| Previous Close | 2.310 |
| Day's Range | 2.250 - 2.349 |
| 52-Week Range | 1.100 - 3.600 |
| Beta | 0.35 |
| Analysts | Strong Buy |
| Price Target | 7.40 (+228.89%) |
| Earnings Date | Aug 11, 2026 |
About ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development o... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ABOS stock is "Strong Buy." The 12-month stock price target is $7.4, which is an increase of 228.89% from the latest price.
News
JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform
HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announ...
Acumen nominates two development candidates in EBD program
Acumen (ABOS) announced the nomination of two development candidates in its Enhanced Brain Delivery, or EBD, program as treatments for AD. Building on preclinical data from both in vitro and…
Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer's Disease
ACU301 and ACU401 were nominated in the EBD program as part of the exercise of Acumen's option under its license agreement with JCR Pharmaceuticals EBD technology represents the only anti-amyloid olig...
Acumen Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
Sabirnetug, a monoclonal antibody targeting Aβ oligomers, is advancing through phase II trials with promising biomarker and safety data. Enhanced brain delivery programs and strategic partnerships aim to further improve efficacy, while the field anticipates combination therapies for Alzheimer's.
Acumen Pharmaceuticals Earnings Call Transcript: Q1 2026
Sabirnetug advanced in phase II with high trial retention and late 2026 data expected. Cash position is strong after a $35.75M raise, supporting operations into 2027. EBD program shows promising preclinical brain exposure and candidate selection is imminent.
Acumen Pharmaceuticals Earnings release: Q1 2026
Acumen Pharmaceuticals released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Acumen Pharmaceuticals Quarterly report: Q1 2026
Acumen Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 12, 2026.
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
NEWTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that t...
Acumen Pharmaceuticals Slides: Corporate presentation
Acumen Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference
NEWTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid ...
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026
NEWTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that t...
Acumen Pharmaceuticals Proxy statement: Proxy filing
Acumen Pharmaceuticals filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Acumen Pharmaceuticals Proxy statement: Proxy filing
Acumen Pharmaceuticals filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Acumen files to sell 10.83M shares of common stock for holders
16:31 EDT Acumen (ABOS) files to sell 10.83M shares of common stock for holders
Acumen Pharmaceuticals Earnings Call Transcript: Q4 2025
Clinical and financial progress marked 2025, with ALTITUDE-AD phase II on track for late 2026 data and strong EBD preclinical results driving a $36M private placement. Cash reserves support operations into early 2027, and the pipeline is positioned for further growth.
Acumen Pharmaceuticals Annual report: Q4 2025
Acumen Pharmaceuticals has published its Q4 2025 annual report on March 26, 2026.
Acumen Pharmaceuticals Earnings release: Q4 2025
Acumen Pharmaceuticals released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
Acumen Pharmaceuticals Registration statement: Registration filing
Acumen Pharmaceuticals filed a registration statement on March 26, 2026, providing details about a securities offering with the SEC.
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
NEWTON, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics tha...
Acumen Pharmaceuticals Slides: Corporate presentation
Acumen Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on March 26, 2026.
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026
NEWTON, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that...
Acumen Pharmaceuticals Transcript: Stifel 2026 Virtual CNS Forum
Sabirnetug, a selective antibody for toxic Abeta oligomers, is in phase II trials for Alzheimer's, with late 2026 data expected to validate its efficacy and safety. Enhanced brain delivery programs and a JCR partnership aim to further improve outcomes, with clinical entry targeted for 2027.
Acumen announces new research findings at Alzheimer’s and Parkinson’s conference
Acumen (ABOS) announced new research findings at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders – AD/PD -, in Copenhagen. The data showcase eff...
Acumen price target raised to $8 from $7 at BTIG
BTIG raised the firm’s price target on Acumen (ABOS) to $8 from $7 and keeps a Buy rating on the shares. Recent updates suggest multiple TfR-binding scaffolds may meaningfully enhance…
Acumen announces $35.75M private placement
Acumen (ABOS) Pharmaceuticals has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $35.75 million of shares of ...